Beltzig, Lea; Schwarzenbach, Christian; Leukel, Petra et al.
Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma CellsCANCERS. Bd. 14. H. 9. 2022
Kraemer, Oliver H.; Schneider, Gunter
Single-cell profiling guided combination therapy of c-Fos and histone deacetylase inhibitors in diffuse large B-cell lymphomaCLINICAL AND TRANSLATIONAL MEDICINE. Bd. 12. H. 5. 2022
Ibrahim, Hany S.; Abdelsalam, Mohamed; Zeyn, Yanira et al.
Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic ActivityINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. Bd. 23. H. 1. 2022
Schwarzenbach, Christian; Tatsch, Larissa; Vilar, Juliana Brandstetter et al.
Targeting c-IAP1, c-IAP2, and Bcl-2 eliminates senescent glioblastoma cells following temozolomide treatmentONCOLOGY RESEARCH AND TREATMENT. Bd. 45. H. SUPPL 3. 2022 S. 49-49
Winkler, Rene; Magdefrau, Ann-Sophie; Piskor, Eva-Maria et al.
Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibitionONCOGENE. Bd. 41. H. 40. 2022 S. 4560-4572
Kaina, Bernd; Beltzig, Lea; Strik, Herwig
Temozolomide - Just a Radiosensitizer?FRONTIERS IN ONCOLOGY. Bd. 12. 2022
Kiweler, Nicole; Schwarz, Helena; Nguyen, Alexandra et al.
The epigenetic modifier HDAC2 and the checkpoint kinase ATM determine the responses of microsatellite instable colorectal cancer cells to 5-fluorouracilCELL BIOLOGY AND TOXICOLOGY. 2022
Petersen, Lara; Stroh, Svenja; Schoettelndreier, Dennis et al.
The Essential Role of Rac1 Glucosylation in Clostridioides difficile Toxin B-Induced Arrest of G1-S TransitionFRONTIERS IN MICROBIOLOGY. Bd. 13. 2022
Gomez-Marin, Elena; Posavec-Marjanovic, Melanija; Zarzuela, Laura et al.
The high mobility group protein HMG20A cooperates with the histone reader PHF14 to modulate TGF beta and Hippo pathwaysNUCLEIC ACIDS RESEARCH. Bd. 50. H. 17. 2022 S. 9838-9857
Arnold, Carina; Demuth, Philipp; Seiwert, Nina et al.
The Mitochondrial Disruptor Devimistat (CPI-613) Synergizes with Genotoxic Anticancer Drugs in Colorectal Cancer Therapy in a Bim-Dependent MannerMOLECULAR CANCER THERAPEUTICS. Bd. 21. H. 1. 2022 S. 100-112